Analytical Data
-
Gene name
EPB42
- Application
-
Alternative Names
PA; Erythrocyte Surface Protein Band 4.2
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P16452
-
Expression Region
Leu475~Ala686
-
Molecular Weight
54kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EPB42, or erythrocyte membrane protein band 4.2, is a critical component of the erythrocyte cytoskeleton that plays a vital role in maintaining the structural integrity and stability of red blood cells. This protein is essential for the interaction between the cytoskeleton and the plasma membrane, contributing to the overall shape and flexibility of erythrocytes. Mutations or deficiencies in EPB42 have been implicated in various hematological disorders, including hereditary elliptocytosis and spheroidal disorders, which can lead to anemia and increased susceptibility to hemolysis. Research into EPB42 recombinants has gained traction in recent years, as scientists seek to elucidate its precise molecular mechanisms and interactions within the erythrocyte. Advances in recombinant DNA technology allow for the production of EPB42 in a laboratory setting, facilitating detailed studies of its structural and functional properties. Understanding EPB42’s role at the molecular level can potentially lead to the development of novel therapeutic approaches for related blood disorders. Moreover, studying EPB42 can provide insights into the broader mechanisms of membrane protein function and cytoskeletal dynamics, which are crucial for normal cellular physiology and can influence various pathophysiological conditions.
